Literature DB >> 6500607

Sensitivity of human pancreatic carcinoma cell line (MIA PaCa-2) to Bisantrene and Theprubicin in vitro.

G Fountzilas, L O Lim, A A Yunis.   

Abstract

We tested the effect of Bisantrene (BS) and Theprubicin (THP-ADR) on cell growth of a human pancreatic carcinoma cell line (MIA PaCa-2). After 1 h exposure ID50 of BS or THP-ADR was 3 X 10(-7) and 5 X 10(-8) M, respectively. Increasing the exposure time from 1 h to continuous exposure for 5d resulted in 11-fold decrease in ID50 for BS and a 6-fold decrease for THP-ADR. Both drugs inhibited [14C]thymidine incorporation to the same extent and caused an accumulation of cells into G2 + M phase of the cell cycle.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6500607     DOI： 10.1007/bf02618873

Source DB:  PubMed          Journal:  In Vitro        ISSN： 0073-5655


  17 in total

Review 1.  Chemotherapy of pancreatic cancer.

Authors:  F P Smith; P S Schein
Journal:  Semin Oncol       Date:  1979-09       Impact factor: 4.929

2.  Lethal effect of adriamycin on the division cycle of HeLa cells.

Authors:  S H Kim; J H Kim
Journal:  Cancer Res       Date:  1972-02       Impact factor: 12.701

3.  Tetrahydropyranyl derivatives of daunomycin and adriamycin.

Authors:  H Umezawa; Y Takahashi; M Kinoshita; H Naganawa; T Masuda; M Ishizuka; K Tatsuta; T Takeuchi
Journal:  J Antibiot (Tokyo)       Date:  1979-10       Impact factor: 2.649

4.  Differential sensitivity of pancreatic adenocarcinoma cell lines to chemotherapeutic agents in culture.

Authors:  B K Chang
Journal:  Cancer Treat Rep       Date:  1983-04

5.  Disposition and metabolic profile of a new antitumor agent: CL 216,942 (bisantrene) in laboratory animals.

Authors:  W H Wu; G Nicolau
Journal:  Cancer Treat Rep       Date:  1982-05

6.  Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase.

Authors:  A A Yunis; G K Arimura; D J Russin
Journal:  Int J Cancer       Date:  1977-01       Impact factor: 7.396

7.  Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.

Authors:  G Powis; J S Kovach
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

8.  Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule.

Authors:  R J Spiegel; R H Blum; M Levin; C A Pinto; J C Wernz; J L Speyer; K S Hoffman; F M Muggia
Journal:  Cancer Res       Date:  1982-01       Impact factor: 12.701

9.  Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.

Authors:  D S Alberts; C Mackel; R Pocelinko; S E Salmon
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

10.  Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining.

Authors:  A Krishan
Journal:  J Cell Biol       Date:  1975-07       Impact factor: 10.539
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.